Coloplast A/S - Selskabsmeddelelse 10/2022 - Årsrapport 2021/22 & Vederlagsrapport 2021/22
Årets resultat i hovedpunkter for 2021/22
- Coloplast leverede en organisk vækst på 6% for regnskabsåret. Omsætning målt i danske kroner steg 16% til 22.579 mio. kr. Den organiske vækst pr. forretningsområde var 7% i Stomi, 6% i Kontinens, 9% i Urologi og 4% i Hud- og Sårpleje (Sårpleje 4%). Stemme og Respiratorisk pleje bidrog med 6 procentpoint til den rapporterede vækst.
- Driftsresultatet (EBIT) før særlige poster var 6.910 mio. kr., en stigning på 9% i forhold til sidste år. Overskudsgraden før særlige poster var 31% mod 33% sidste år og inkluderer afskrivninger på immaterielle anlægsaktiver på 152 mio. kr. relateret til købet af Atos Medical. Overskudsgraden (EBIT-margin) efter særlige poster var 29%, bl.a. som følge af 471 mio. kr. i særlige poster1.
- Afkastet af den investerede kapital efter skat før særlige poster var 27% mod 45% sidste år, hvilket bl.a. skyldes den negative effekt af opkøbet af Atos Medical. Indtjeningen pr. aktie (EPS), udvandet, før særlige poster steg 3% til 23,82 kr.
- Bestyrelsen anbefaler, at der udbetales et yderligere udbytte på 15,00 kr. pr. aktie, hvormed den samlede udbyttebetaling for året vil være 20,00 kr. pr. aktie mod 19,00 kr. pr. aktie sidste år.
Finansielle forventninger for 2022/23 – organisk omsætningsvækst på 7-8% og en overskudsgrad på 28-30%
- Den forventede organiske omsætningsvækst er 7-8% i faste valutakurser. Den rapporterede vækst i danske kroner forventes at være 11-12% og inkluderer et vækstbidrag fra opkøbet af Atos Medical på omkring 3 procentpoint (4 måneders effekt) samt positiv påvirkning fra valutakurser på omkring 1 procentpoint.
- Den rapporterede overskudsgrad forventes at være 28-30% som følge af stigende inputomkostninger, især for råvarer og elektricitet i Ungarn, delvist opvejet af driftsbesparelser, effektivitetsforbedringer og fokus på omkostningsstyring.
- Anlægsinvesteringer forventes at udgøre ca. 1,4 mia. kr. Den effektive skatteprocent forventes at blive ca. 21%.
Se Årsrapporten 2021/22 og Vederlagsrapport 2021/22 i nedenstående links.
Vores mission
At gøre livet lettere for mennesker
med behov inden for intim sundhedspleje
Vores værdier
Nærhed... for bedre at forstå
Passion... for at gøre en forskel
Respekt og ansvarlighed... for at vejlede os
Vores vision
At sætte den globale standard
for at lytte og handle
For yderligere information, kontakt venligst
Investorer og analytikere
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tlf. 4911 1111
Aleksandra Dimovska
Director, Investor Relations
Tlf. 4911 1800 / 4911 2458
Email: dkadim@coloplast.com
Kristine Husted Munk
Senior Manager, Investor Relations
Tlf. 4911 1800 / 4911 3266
Email: dkkhu@coloplast.com
Presse og medier
Peter Mønster
Sr. Media Relations Manager
Tlf. 4911 2608
Email: dkpete@coloplast.com
Adresse
Coloplast A/S
Holtedam 1
DK-3050 Humlebæk
Danmark
CVR nr. 69749917
Hjemmeside
www.coloplast.com
Denne meddelelse foreligger på dansk og engelsk. I tvivlstilfælde er den engelske udgave gældende.
Coloplast udvikler, producerer og markedsfører produkter og serviceydelser, der gør livet lettere for mennesker med meget personlige og private lidelser. Vi arbejder tæt sammen med brugerne af vores produkter for at udvikle nye produkter, der løser deres særlige behov. Vi kalder det intim sundhedspleje. Coloplast har fem forretningsområder: Stomi, Kontinens, Hud- og Sårpleje, Urologi og Stemme og Respiratorisk Pleje. Vi er et globalt selskabet med mere end 14.500 ansatte.
Coloplast-logoet er et registreret varemærke tilhørende Coloplast A/S. © 2022-11.
Alle rettigheder forbeholdes. Coloplast A/S, 3050 Humlebæk, Danmark.
Vedhæftede filer
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)11.12.2023 01:30:00 CET | Press release
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data1-5 Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the 24-week randomized controlled period, including transfusion avoidance and near-normal hemoglobin-levels (≥12 g/dL) in the majority of patients1 Fabhalta was recently approved by the FDA for adults with PNH, including for both previously treated and treatment-naive patients6 Basel, December 11, 2023 – Novartis today announced results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who h
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia10.12.2023 18:05:00 CET | Press release
Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC:Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observedPoster presentation at American Society of Hematology (ASH) Annual meeting Registrational PRESent-2 and PRESent-3 studies of SerpinPC in hemophilia B are ongoing BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemoph
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo